TABLE 3.
Antimicrobial group and gene | Total no. (%) of isolates | No. (%) of isolates of each fimbrial typea |
Kappa | P valueb | |
---|---|---|---|---|---|
F4 | F18 | ||||
Beta-lactams | |||||
blaTEM-1A | 4 (4.4) | 4 (5.8) | 0 | 0.933 | 0.0001 |
blaTEM-1B | 42 (46.7) | 30 (43.5) | 12 (57.1) | ||
blaTEM-30 | 1 (1.1) | 1 (1.4) | 0 | ||
Aminoglycosides | |||||
aph (phosphotransferases) | 58 (64.4) | 50 (72.5) | 8 (38.1) | 0.927 | 0.0001 |
aadA (nucleotidyltransferases) | 57 (63.3) | 42 (60.9) | 15 (71.4) | ||
aac (acetyltransferases) | 9 (10) | 8 (11.6) | 1 (4.8) | ||
Phenicols | |||||
catA1 | 3 (3.3) | 3 (4.3) | 0 | 1.000 | 0.0001 |
cmlA1 | 8 (8.9) | 2 (2.9) | 6 (28.6) | ||
floR | 5 (5.6) | 5 (7.2) | 0 | ||
Macrolides | |||||
mdf(A) | 90 (100) | 69 (100) | 21 (100) | ND | ND |
mph(A) | 8 (8.9) | 8 (11.6) | 0 | ||
mph(B) | 7 (7.8) | 7 (10.1) | 0 | ||
erm(B) | 9 (10) | 9 (13) | 0 | ||
Lincosamides | |||||
lnu(F) | 5 (5.6) | 5 (7.2) | 0 | ND | ND |
lnu(G) | 5 (5.6) | 5 (7.2) | 0 | ||
Sulfonamides | |||||
sul1 | 30 (33.3) | 28 (40.6) | 2 (9.5) | 0.898 | 0.0001 |
sul2 | 42 (46.7) | 35 (50.7) | 7 (33.3) | ||
sul3 | 9 (10) | 3 (4.3) | 6 (28.6) | ||
Tetracycline | |||||
tet(A) | 40 (44.4) | 32 (46.4) | 8 (38.1) | 1.000 | 0.0001 |
tet(B) | 13 (14.4) | 12 (17.4) | 1 (4.8) | ||
tet(X) | 1 (1.1) | 1 (1.4) | 0 | ||
Trimethoprim | |||||
dfrA1 | 34 (37.8) | 27 (39.1) | 7 (33.3) | 0.978 | 0.0001 |
dfrA5 | 2 (2.2) | 2 (2.9) | 0 | ||
dfrA12 | 8 (8.9) | 2 (2.9) | 6 (28.6) | ||
dfrA14 | 5 (5.6) | 5 (7.2) | 0 | ||
dfrA17 | 2 (2.2) | 2 (2.9) | 0 |
Percentage is estimated based on the total number of strains associated with each fimbrial type.
A P value of <0.05 is considered significant.